Pediatric Neurosurgery, Children's Hospital Colorado, University of Colorado Denver, Aurora, CO 80045, USA.
J Neurooncol. 2012 Nov;110(2):271-8. doi: 10.1007/s11060-012-0966-5. Epub 2012 Aug 23.
Craniopharyngioma is histologically benign and associated with high survival rates but poor quality of life. The SEER Program is among the most cited data sources regarding malignancies in the United States. SEER began collecting data regarding craniopharyngiomain 2004. SEER-STAT v7.0.5 was utilized to identify patients (January 1, 2004-December 31, 2008) with ICD-O-3 codes for craniopharyngioma. Age was categorized into 3 groups: ≤19, 20-34, and ≥35 years, as was surgical intervention: none, subtotal resection, and gross total/radical resection. Demographic, initial treatment, and follow-up data were collected. 635/662 (95.9 %) patients had complete data. Incidence per million patient-years by age group was 1.9, 1.1, and 1.9, respectively (p < 0.0001). There was bimodal incidence, with peaks at 5-9 and 60-74 years. Surgery occurred in 528 patients (83.1 %), without association between age group and extent of surgery (p = 0.14). Radiation was delivered in 139 (21.9 %) cases, with no association between treatment and extent of surgery (p = 0.73) or age group (p = 0.14). Median follow-up was 23 months. Overall and Cause-specific Survival were 87.9 and 94.5 %, respectively. Neither was associated with extent of surgery but both were positively associated with radiation (p = 0.0003 and 0.0007, respectively). There was no difference in OS or CSS when comparing STR ± RT versus GTR alone (p = 0.38 and 0.56, respectively). SEER provides reliable demographic and survival data regarding craniopharyngioma. SEER's focus on mortality statistics limits utility for outcomes studies in tumors with high survival rates, such as craniopharyngioma. Initial treatment data from SEER varies somewhat from current literature, meriting further investigation.
颅咽管瘤在组织学上是良性的，存活率高，但生活质量差。SEER 计划是美国最常被引用的恶性肿瘤数据来源之一。SEER 于 2004 年开始收集颅咽管瘤的数据。利用 SEER-STAT v7.0.5 识别出 2004 年 1 月 1 日至 2008 年 12 月 31 日 ICD-O-3 编码为颅咽管瘤的患者。年龄分为 3 组：≤19 岁、20-34 岁和≥35 岁，手术干预也分为 3 组：无、次全切除和大体全/根治性切除。收集了人口统计学、初始治疗和随访数据。635/662（95.9%）例患者资料完整。按年龄组计算的每百万患者年发病率分别为 1.9、1.1 和 1.9（p<0.0001）。发病率呈双峰型，分别在 5-9 岁和 60-74 岁达到高峰。528 例（83.1%）患者接受了手术，年龄组与手术范围之间无关联（p=0.14）。139 例（21.9%）患者接受了放疗，治疗方法与手术范围之间无关联（p=0.73），与年龄组之间也无关联（p=0.14）。中位随访时间为 23 个月。总生存率和病因特异性生存率分别为 87.9%和 94.5%。这两者都与手术范围无关，但都与放疗呈正相关（p=0.0003 和 0.0007）。STR±RT 与 GTR 相比，OS 或 CSS 无差异（p=0.38 和 0.56）。SEER 提供了关于颅咽管瘤的可靠人口统计学和生存数据。SEER 对死亡率统计数据的关注限制了其在生存率较高的肿瘤（如颅咽管瘤）的结局研究中的应用。SEER 的初始治疗数据与当前文献略有不同，值得进一步研究。
